. . . to use people as human guinea pigs for orphan or other drug trials when there is little or no hope of the new drug being made available on the NHS.
I was mulling over the events leading up to NICE's recent rejection of Ruxolitinib for NHS use in the UK after months of extensive trialling and evidence gathering both here and previously in the US. After reading on our forum the dilemma currently facing some of you regarding trials I was left wondering if in the light of their decision for MF sufferers is there any point in pressing on with similar trials for ET/PV patients. Or are they just raising false hopes for those people it works well for who might have it free for a the duration of the trial and a bit beyond only to be denied it and possibly start to backtrack.
Then again maybe the drug company will simply pull out of similar trials in the UK.
Or would the potential of wider application and increased end user numbers - there are about 600 MF patients in UK and not even half those would need Rux - have a positive bearing and encourage the drug provider to decrease the price. Or would NICE simply see it as a greater cost the NHS.
These are just some of my random thoughts. I think it's a political hot potato and no doubt greater minds than mine will be mulling over the endless possibilties.